NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Eye drops could replace needles for wet AMD? new trial underway
Disease control OngoingThis study tests whether KHK4951 eye drops can safely improve vision in people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 180 participants will use the drops or a placebo to see if they reduce fluid buildup and preserve eyesight. The g…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE2 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 10:48 UTC
-
New eye implant could reduce need for frequent shots in wet AMD
Disease control OngoingThis study tests a new implant (AR-14034) that slowly releases medicine inside the eye to treat wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the implant is safe and can keep vision stable longer than current standard injections…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1, PHASE2 • Sponsor: Alcon Research • Aim: Disease control
Last updated May 26, 2026 10:47 UTC
-
One shot could replace dozens: gene therapy trial for blinding eye disease
Disease control OngoingThis Phase 3 study tests a single injection of a gene therapy called Ixo-vec in 311 people with wet age-related macular degeneration, a leading cause of vision loss. The goal is to see if one treatment can control the disease as well as or better than current standard-of-care eye…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 26, 2026 10:45 UTC
-
Eye implant refill every 36 weeks could ease treatment burden for AMD patients
Disease control OngoingThis study tests if refilling a tiny eye implant every 36 weeks works as well as refilling it every 24 weeks for people with wet age-related macular degeneration (nAMD). The implant delivers medicine to control the disease and prevent vision loss. About 451 participants who have …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 10:43 UTC
-
New shot every 6 months could ease burden of wet AMD treatment
Disease control OngoingThis study tests whether an eye injection called faricimab, given every 24 weeks, can safely maintain or improve vision in people with wet age-related macular degeneration (nAMD) who have not been treated before. About 274 participants will receive the drug and be followed for 10…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE4 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 10:34 UTC
-
Gene therapy for wet AMD passes early safety check in small study
Disease control OngoingThis study checks the long-term safety of a gene therapy called EXG102-031 for wet age-related macular degeneration (AMD), a condition that causes blurry or lost central vision. Twelve people who already received the gene therapy in an earlier study will be followed for up to 4 y…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Gene therapy shot could replace monthly eye injections for wet AMD
Disease control OngoingThis study tests a gene therapy called RGX-314 as a potential one-time treatment for wet age-related macular degeneration (nAMD), a leading cause of vision loss. Currently, patients need frequent eye injections to control the disease. The trial involves about 146 adults aged 50-8…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New eye injection for macular degeneration passes early safety check
Disease control OngoingThis early-stage trial tests the safety of an experimental drug called OCU-10-C-110 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The study involves 24 participants who receive one or more injections into the eye. Researchers monitor…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Ocugenix Corporation • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Japanese study tracks Real-World use of eye injection for blurry vision
Knowledge-focused OngoingThis study looks at how aflibercept 8 mg, a drug injected into the eye, is used in routine care for people with age-related macular degeneration or diabetic macular edema in Japan. Researchers will analyze existing health records from about 3000 patients to understand who gets th…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 26, 2026 10:46 UTC
-
New eye Drug's Real-World impact under scrutiny in 2,500-Patient study
Knowledge-focused OngoingThis study watches how well aflibercept 8 mg works in real life for people with vision loss from age-related macular degeneration or diabetic eye swelling. Researchers will track vision changes over 12 months using routine doctor visits. No extra tests or visits are required—just…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC